BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ADX71149: Phase IIa started

Johnson & Johnson began a European Phase IIa trial to evaluate twice-daily 50-150 mg ADX71149 in about 105 patients. The trial will be divided into 2 parts - a 12-week,...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >